nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—Alzheimer's disease—amyotrophic lateral sclerosis	0.807	1	CtDrD
Galantamine—CHRNB3—pons—amyotrophic lateral sclerosis	0.00713	0.142	CbGeAlD
Galantamine—CHRNG—tongue—amyotrophic lateral sclerosis	0.00284	0.0565	CbGeAlD
Galantamine—CHRNB3—hindbrain—amyotrophic lateral sclerosis	0.00277	0.055	CbGeAlD
Galantamine—CHRNA9—embryo—amyotrophic lateral sclerosis	0.00261	0.052	CbGeAlD
Galantamine—BCHE—diaphragm—amyotrophic lateral sclerosis	0.00254	0.0505	CbGeAlD
Galantamine—Paranoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00236	0.0305	CcSEcCtD
Galantamine—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0257	CcSEcCtD
Galantamine—CHRNA1—tongue—amyotrophic lateral sclerosis	0.00188	0.0374	CbGeAlD
Galantamine—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00177	0.0229	CcSEcCtD
Galantamine—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00171	0.0221	CcSEcCtD
Galantamine—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00165	0.0213	CcSEcCtD
Galantamine—CHRNB3—brainstem—amyotrophic lateral sclerosis	0.00159	0.0316	CbGeAlD
Galantamine—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0198	CcSEcCtD
Galantamine—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0198	CcSEcCtD
Galantamine—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0198	CcSEcCtD
Galantamine—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0192	CcSEcCtD
Galantamine—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.00147	0.019	CcSEcCtD
Galantamine—CHRNA4—peripheral nervous system—amyotrophic lateral sclerosis	0.00142	0.0282	CbGeAlD
Galantamine—Apathy—Riluzole—amyotrophic lateral sclerosis	0.0014	0.0182	CcSEcCtD
Galantamine—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00139	0.018	CcSEcCtD
Galantamine—CHRNA6—brainstem—amyotrophic lateral sclerosis	0.00132	0.0263	CbGeAlD
Galantamine—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00125	0.0161	CcSEcCtD
Galantamine—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00125	0.0161	CcSEcCtD
Galantamine—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00117	0.0151	CcSEcCtD
Galantamine—CHRNA4—nerve—amyotrophic lateral sclerosis	0.00111	0.022	CbGeAlD
Galantamine—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00108	0.014	CcSEcCtD
Galantamine—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00105	0.0136	CcSEcCtD
Galantamine—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.001	0.013	CcSEcCtD
Galantamine—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.001	0.013	CcSEcCtD
Galantamine—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.001	0.013	CcSEcCtD
Galantamine—Melaena—Riluzole—amyotrophic lateral sclerosis	0.000979	0.0127	CcSEcCtD
Galantamine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.000968	0.0125	CcSEcCtD
Galantamine—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.000921	0.0119	CcSEcCtD
Galantamine—CHRNA5—nervous system—amyotrophic lateral sclerosis	0.000915	0.0182	CbGeAlD
Galantamine—CHRNA5—central nervous system—amyotrophic lateral sclerosis	0.000881	0.0175	CbGeAlD
Galantamine—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.000879	0.0114	CcSEcCtD
Galantamine—CHRNG—medulla oblongata—amyotrophic lateral sclerosis	0.00087	0.0173	CbGeAlD
Galantamine—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.000837	0.0108	CcSEcCtD
Galantamine—CHRNB3—nervous system—amyotrophic lateral sclerosis	0.000831	0.0165	CbGeAlD
Galantamine—CHRNA4—hindbrain—amyotrophic lateral sclerosis	0.000829	0.0165	CbGeAlD
Galantamine—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.000814	0.0105	CcSEcCtD
Galantamine—CHRNB3—central nervous system—amyotrophic lateral sclerosis	0.0008	0.0159	CbGeAlD
Galantamine—Injury—Riluzole—amyotrophic lateral sclerosis	0.000792	0.0102	CcSEcCtD
Galantamine—CHRNB3—cerebellum—amyotrophic lateral sclerosis	0.000782	0.0156	CbGeAlD
Galantamine—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.000768	0.00993	CcSEcCtD
Galantamine—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000755	0.00977	CcSEcCtD
Galantamine—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.000749	0.00968	CcSEcCtD
Galantamine—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.000746	0.00964	CcSEcCtD
Galantamine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.000722	0.00934	CcSEcCtD
Galantamine—CHRNA5—brain—amyotrophic lateral sclerosis	0.0007	0.0139	CbGeAlD
Galantamine—CHRNA6—nervous system—amyotrophic lateral sclerosis	0.000694	0.0138	CbGeAlD
Galantamine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.000692	0.00895	CcSEcCtD
Galantamine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000684	0.00885	CcSEcCtD
Galantamine—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.000677	0.00875	CcSEcCtD
Galantamine—CHRNA6—central nervous system—amyotrophic lateral sclerosis	0.000668	0.0133	CbGeAlD
Galantamine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.000665	0.0086	CcSEcCtD
Galantamine—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.000662	0.00857	CcSEcCtD
Galantamine—CHRNA6—cerebellum—amyotrophic lateral sclerosis	0.000653	0.013	CbGeAlD
Galantamine—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00833	CcSEcCtD
Galantamine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000642	0.0083	CcSEcCtD
Galantamine—CHRNB3—brain—amyotrophic lateral sclerosis	0.000635	0.0126	CbGeAlD
Galantamine—CHRNB4—nervous system—amyotrophic lateral sclerosis	0.00063	0.0125	CbGeAlD
Galantamine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000629	0.00814	CcSEcCtD
Galantamine—CHRNB4—central nervous system—amyotrophic lateral sclerosis	0.000606	0.0121	CbGeAlD
Galantamine—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.000605	0.00782	CcSEcCtD
Galantamine—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000603	0.0078	CcSEcCtD
Galantamine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000581	0.00752	CcSEcCtD
Galantamine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000569	0.00736	CcSEcCtD
Galantamine—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000564	0.0073	CcSEcCtD
Galantamine—Depression—Riluzole—amyotrophic lateral sclerosis	0.000559	0.00723	CcSEcCtD
Galantamine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00055	0.00711	CcSEcCtD
Galantamine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000545	0.00705	CcSEcCtD
Galantamine—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000535	0.00692	CcSEcCtD
Galantamine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00053	0.00686	CcSEcCtD
Galantamine—CHRNB2—medulla oblongata—amyotrophic lateral sclerosis	0.00053	0.0105	CbGeAlD
Galantamine—CHRNA6—brain—amyotrophic lateral sclerosis	0.00053	0.0105	CbGeAlD
Galantamine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000529	0.00684	CcSEcCtD
Galantamine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000513	0.00663	CcSEcCtD
Galantamine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000506	0.00654	CcSEcCtD
Galantamine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000505	0.00653	CcSEcCtD
Galantamine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000503	0.00651	CcSEcCtD
Galantamine—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000503	0.00651	CcSEcCtD
Galantamine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.000501	0.00648	CcSEcCtD
Galantamine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000497	0.00643	CcSEcCtD
Galantamine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000496	0.00641	CcSEcCtD
Galantamine—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000495	0.0064	CcSEcCtD
Galantamine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000494	0.00638	CcSEcCtD
Galantamine—CHRNB4—brain—amyotrophic lateral sclerosis	0.000481	0.00958	CbGeAlD
Galantamine—CHRNA4—brainstem—amyotrophic lateral sclerosis	0.000475	0.00945	CbGeAlD
Galantamine—CHRNB2—spinal cord—amyotrophic lateral sclerosis	0.000473	0.0094	CbGeAlD
Galantamine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000471	0.00609	CcSEcCtD
Galantamine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000467	0.00604	CcSEcCtD
Galantamine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000457	0.00591	CcSEcCtD
Galantamine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000455	0.00588	CcSEcCtD
Galantamine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00045	0.00582	CcSEcCtD
Galantamine—CHRNB1—medulla oblongata—amyotrophic lateral sclerosis	0.000445	0.00885	CbGeAlD
Galantamine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000441	0.0057	CcSEcCtD
Galantamine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000438	0.00567	CcSEcCtD
Galantamine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000432	0.00559	CcSEcCtD
Galantamine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00043	0.00556	CcSEcCtD
Galantamine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000429	0.00555	CcSEcCtD
Galantamine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000426	0.00551	CcSEcCtD
Galantamine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000424	0.00548	CcSEcCtD
Galantamine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000421	0.00545	CcSEcCtD
Galantamine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000411	0.00531	CcSEcCtD
Galantamine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000407	0.00526	CcSEcCtD
Galantamine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000405	0.00524	CcSEcCtD
Galantamine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000403	0.00521	CcSEcCtD
Galantamine—CHRNB2—nervous system—amyotrophic lateral sclerosis	0.000398	0.00792	CbGeAlD
Galantamine—CHRNB1—spinal cord—amyotrophic lateral sclerosis	0.000397	0.00789	CbGeAlD
Galantamine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000395	0.00511	CcSEcCtD
Galantamine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000394	0.00509	CcSEcCtD
Galantamine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000393	0.00508	CcSEcCtD
Galantamine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000387	0.00501	CcSEcCtD
Galantamine—CHRNA3—nervous system—amyotrophic lateral sclerosis	0.000386	0.00769	CbGeAlD
Galantamine—ACHE—medulla oblongata—amyotrophic lateral sclerosis	0.000386	0.00767	CbGeAlD
Galantamine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000385	0.00498	CcSEcCtD
Galantamine—CHRNB2—central nervous system—amyotrophic lateral sclerosis	0.000384	0.00763	CbGeAlD
Galantamine—Cough—Riluzole—amyotrophic lateral sclerosis	0.000382	0.00495	CcSEcCtD
Galantamine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00038	0.00491	CcSEcCtD
Galantamine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000378	0.00489	CcSEcCtD
Galantamine—CHRNB2—cerebellum—amyotrophic lateral sclerosis	0.000375	0.00746	CbGeAlD
Galantamine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000373	0.00483	CcSEcCtD
Galantamine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000373	0.00483	CcSEcCtD
Galantamine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000373	0.00483	CcSEcCtD
Galantamine—CHRNA3—central nervous system—amyotrophic lateral sclerosis	0.000372	0.0074	CbGeAlD
Galantamine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000372	0.00481	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000371	0.00479	CcSEcCtD
Galantamine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000369	0.00477	CcSEcCtD
Galantamine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000365	0.00472	CcSEcCtD
Galantamine—CHRNA3—cerebellum—amyotrophic lateral sclerosis	0.000364	0.00723	CbGeAlD
Galantamine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000361	0.00466	CcSEcCtD
Galantamine—CHRNA2—nervous system—amyotrophic lateral sclerosis	0.000359	0.00714	CbGeAlD
Galantamine—Shock—Riluzole—amyotrophic lateral sclerosis	0.000352	0.00455	CcSEcCtD
Galantamine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000351	0.00454	CcSEcCtD
Galantamine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00035	0.00453	CcSEcCtD
Galantamine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000349	0.00452	CcSEcCtD
Galantamine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000347	0.00449	CcSEcCtD
Galantamine—CHRNA2—central nervous system—amyotrophic lateral sclerosis	0.000346	0.00688	CbGeAlD
Galantamine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000346	0.00447	CcSEcCtD
Galantamine—ACHE—spinal cord—amyotrophic lateral sclerosis	0.000344	0.00684	CbGeAlD
Galantamine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00441	CcSEcCtD
Galantamine—CHRNA2—cerebellum—amyotrophic lateral sclerosis	0.000338	0.00672	CbGeAlD
Galantamine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000334	0.00432	CcSEcCtD
Galantamine—CHRNA1—brain—amyotrophic lateral sclerosis	0.000331	0.00658	CbGeAlD
Galantamine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000326	0.00421	CcSEcCtD
Galantamine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000324	0.00418	CcSEcCtD
Galantamine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000321	0.00415	CcSEcCtD
Galantamine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000318	0.00411	CcSEcCtD
Galantamine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000315	0.00407	CcSEcCtD
Galantamine—CHRNB1—cerebellum—amyotrophic lateral sclerosis	0.000315	0.00626	CbGeAlD
Galantamine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000314	0.00625	CbGeAlD
Galantamine—CHRFAM7A—nervous system—amyotrophic lateral sclerosis	0.000313	0.00622	CbGeAlD
Galantamine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000311	0.00402	CcSEcCtD
Galantamine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000309	0.00399	CcSEcCtD
Galantamine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000308	0.00399	CcSEcCtD
Galantamine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000306	0.00396	CcSEcCtD
Galantamine—CHRNB2—brain—amyotrophic lateral sclerosis	0.000305	0.00606	CbGeAlD
Galantamine—CHRFAM7A—central nervous system—amyotrophic lateral sclerosis	0.000301	0.00598	CbGeAlD
Galantamine—CHRNA4—spinal cord—amyotrophic lateral sclerosis	0.000296	0.00588	CbGeAlD
Galantamine—CHRNA3—brain—amyotrophic lateral sclerosis	0.000295	0.00587	CbGeAlD
Galantamine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000295	0.00381	CcSEcCtD
Galantamine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000293	0.00378	CcSEcCtD
Galantamine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000283	0.00366	CcSEcCtD
Galantamine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000283	0.00366	CcSEcCtD
Galantamine—CHRNA2—brain—amyotrophic lateral sclerosis	0.000275	0.00546	CbGeAlD
Galantamine—ACHE—cerebellum—amyotrophic lateral sclerosis	0.000273	0.00542	CbGeAlD
Galantamine—BCHE—brainstem—amyotrophic lateral sclerosis	0.000272	0.00541	CbGeAlD
Galantamine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000264	0.00341	CcSEcCtD
Galantamine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000257	0.00332	CcSEcCtD
Galantamine—CHRNB1—brain—amyotrophic lateral sclerosis	0.000255	0.00508	CbGeAlD
Galantamine—CHRNA7—nervous system—amyotrophic lateral sclerosis	0.000252	0.00502	CbGeAlD
Galantamine—CHRNA4—nervous system—amyotrophic lateral sclerosis	0.000249	0.00495	CbGeAlD
Galantamine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000245	0.00317	CcSEcCtD
Galantamine—CHRNA7—central nervous system—amyotrophic lateral sclerosis	0.000243	0.00483	CbGeAlD
Galantamine—CHRNA4—central nervous system—amyotrophic lateral sclerosis	0.00024	0.00477	CbGeAlD
Galantamine—CHRFAM7A—brain—amyotrophic lateral sclerosis	0.000239	0.00475	CbGeAlD
Galantamine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000237	0.00306	CcSEcCtD
Galantamine—CHRNA4—cerebellum—amyotrophic lateral sclerosis	0.000234	0.00466	CbGeAlD
Galantamine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000227	0.00294	CcSEcCtD
Galantamine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000226	0.00292	CcSEcCtD
Galantamine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000225	0.00291	CcSEcCtD
Galantamine—Headache—Riluzole—amyotrophic lateral sclerosis	0.000224	0.0029	CcSEcCtD
Galantamine—ACHE—brain—amyotrophic lateral sclerosis	0.000222	0.00441	CbGeAlD
Galantamine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000212	0.00275	CcSEcCtD
Galantamine—CHRNA7—brain—amyotrophic lateral sclerosis	0.000193	0.00384	CbGeAlD
Galantamine—CHRNA4—brain—amyotrophic lateral sclerosis	0.00019	0.00379	CbGeAlD
Galantamine—BCHE—medulla oblongata—amyotrophic lateral sclerosis	0.00019	0.00377	CbGeAlD
Galantamine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00018	0.00358	CbGeAlD
Galantamine—BCHE—spinal cord—amyotrophic lateral sclerosis	0.000169	0.00336	CbGeAlD
Galantamine—CHRNB4—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000147	0.00225	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000147	0.00224	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000147	0.00224	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000147	0.00224	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000145	0.00222	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000145	0.00222	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.000144	0.00221	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000143	0.00219	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000143	0.00219	CbGpPWpGaD
Galantamine—BCHE—nervous system—amyotrophic lateral sclerosis	0.000142	0.00283	CbGeAlD
Galantamine—ACHE—Glycerophospholipid biosynthesis—CHAT—amyotrophic lateral sclerosis	0.000141	0.00216	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000141	0.00216	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000141	0.00216	CbGpPWpGaD
Galantamine—ACHE—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.00014	0.00214	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000139	0.00213	CbGpPWpGaD
Galantamine—BCHE—central nervous system—amyotrophic lateral sclerosis	0.000137	0.00273	CbGeAlD
Galantamine—CHRND—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000137	0.00209	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.000136	0.00207	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000136	0.00207	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000135	0.00207	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000134	0.00205	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000134	0.00205	CbGpPWpGaD
Galantamine—BCHE—cerebellum—amyotrophic lateral sclerosis	0.000134	0.00267	CbGeAlD
Galantamine—CHRNA3—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000133	0.00203	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000133	0.00203	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000132	0.00202	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000131	0.002	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000131	0.002	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PLB1—amyotrophic lateral sclerosis	0.00013	0.00199	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000129	0.00198	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000127	0.00195	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000127	0.00195	CbGpPWpGaD
Galantamine—BCHE—Glycerophospholipid biosynthesis—CHAT—amyotrophic lateral sclerosis	0.000126	0.00193	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000126	0.00193	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000126	0.00193	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000126	0.00193	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000126	0.00193	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000125	0.00192	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000125	0.00192	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000125	0.00192	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.000125	0.00191	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000125	0.00191	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000125	0.00191	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000124	0.0019	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000121	0.00185	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000121	0.00185	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00012	0.00183	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00012	0.00183	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00012	0.00183	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000118	0.00181	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000118	0.00181	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000118	0.00181	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000118	0.00181	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000118	0.0018	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000116	0.00178	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000116	0.00178	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PLB1—amyotrophic lateral sclerosis	0.000116	0.00178	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000114	0.00174	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000112	0.00172	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000112	0.00172	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000112	0.00172	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000112	0.00172	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000111	0.0017	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000111	0.0017	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000111	0.0017	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000111	0.00169	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00011	0.00169	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000109	0.00167	CbGpPWpGaD
Galantamine—BCHE—brain—amyotrophic lateral sclerosis	0.000109	0.00217	CbGeAlD
Galantamine—CHRNA2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000107	0.00163	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000106	0.00162	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000104	0.00159	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000104	0.00159	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000103	0.00157	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000103	0.00157	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000103	0.00157	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000103	0.00157	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000102	0.00156	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000102	0.00156	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.0001	0.00153	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	9.91e-05	0.00152	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—CHAT—amyotrophic lateral sclerosis	9.86e-05	0.00151	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—NEFL—amyotrophic lateral sclerosis	9.76e-05	0.00149	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	9.67e-05	0.00148	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	9.65e-05	0.00148	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—CHAT—amyotrophic lateral sclerosis	9.65e-05	0.00148	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	9.62e-05	0.00147	CbGpPWpGaD
Galantamine—CYP3A4—nervous system—amyotrophic lateral sclerosis	9.59e-05	0.00191	CbGeAlD
Galantamine—CHRNA4—Neuronal System—GRIA2—amyotrophic lateral sclerosis	9.58e-05	0.00147	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—CHAT—amyotrophic lateral sclerosis	9.55e-05	0.00146	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	9.55e-05	0.00146	CbGpPWpGaD
Galantamine—CYP2D6—nervous system—amyotrophic lateral sclerosis	9.44e-05	0.00188	CbGeAlD
Galantamine—CHRNA4—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	9.25e-05	0.00142	CbGpPWpGaD
Galantamine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	9.23e-05	0.00184	CbGeAlD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	9.16e-05	0.0014	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	9.15e-05	0.0014	CbGpPWpGaD
Galantamine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	9.09e-05	0.00181	CbGeAlD
Galantamine—CHRNA2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	9.08e-05	0.00139	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—CHAT—amyotrophic lateral sclerosis	9.08e-05	0.00139	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	9.07e-05	0.00139	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	8.92e-05	0.00137	CbGpPWpGaD
Galantamine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	8.88e-05	0.00177	CbGeAlD
Galantamine—BCHE—Phospholipid metabolism—CHAT—amyotrophic lateral sclerosis	8.8e-05	0.00135	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—IGFALS—amyotrophic lateral sclerosis	8.72e-05	0.00133	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	8.62e-05	0.00132	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	8.62e-05	0.00132	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	8.6e-05	0.00132	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	8.51e-05	0.0013	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—NEFL—amyotrophic lateral sclerosis	8.46e-05	0.0013	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	8.09e-05	0.00124	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	7.96e-05	0.00122	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	7.95e-05	0.00122	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	7.88e-05	0.00121	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	7.87e-05	0.0012	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—CHAT—amyotrophic lateral sclerosis	7.87e-05	0.0012	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—IGFALS—amyotrophic lateral sclerosis	7.78e-05	0.00119	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	7.69e-05	0.00118	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	7.64e-05	0.00117	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	7.41e-05	0.00113	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	7.33e-05	0.00112	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	7.33e-05	0.00112	CbGpPWpGaD
Galantamine—CYP2D6—brain—amyotrophic lateral sclerosis	7.21e-05	0.00143	CbGeAlD
Galantamine—BCHE—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	7.03e-05	0.00108	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	7.01e-05	0.00107	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	6.99e-05	0.00107	CbGpPWpGaD
Galantamine—ACHE—Glycerophospholipid biosynthesis—PLA2G4A—amyotrophic lateral sclerosis	6.98e-05	0.00107	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—GRIA2—amyotrophic lateral sclerosis	6.84e-05	0.00105	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	6.82e-05	0.00104	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	6.61e-05	0.00101	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	6.61e-05	0.00101	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—PIGW—amyotrophic lateral sclerosis	6.61e-05	0.00101	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	6.6e-05	0.00101	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	6.54e-05	0.001	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	6.54e-05	0.001	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	6.53e-05	0.001	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	6.5e-05	0.000995	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	6.48e-05	0.000992	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	6.42e-05	0.000982	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	6.24e-05	0.000955	CbGpPWpGaD
Galantamine—BCHE—Glycerophospholipid biosynthesis—PLA2G4A—amyotrophic lateral sclerosis	6.23e-05	0.000953	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	6.11e-05	0.000936	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—GRIA2—amyotrophic lateral sclerosis	6.1e-05	0.000934	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	6.04e-05	0.000925	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	6.04e-05	0.000924	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—NEFL—amyotrophic lateral sclerosis	6.04e-05	0.000924	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—PIGW—amyotrophic lateral sclerosis	5.89e-05	0.000902	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	5.89e-05	0.000902	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	5.83e-05	0.000892	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	5.81e-05	0.00089	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	5.8e-05	0.000888	CbGpPWpGaD
Galantamine—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	5.72e-05	0.000876	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	5.61e-05	0.000859	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—CHAT—amyotrophic lateral sclerosis	5.61e-05	0.000859	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	5.45e-05	0.000835	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	5.39e-05	0.000825	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—NEFL—amyotrophic lateral sclerosis	5.39e-05	0.000825	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—CHAT—amyotrophic lateral sclerosis	5.01e-05	0.000767	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	5.01e-05	0.000767	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	5.01e-05	0.000766	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	5e-05	0.000766	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	4.93e-05	0.000755	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—IGF1—amyotrophic lateral sclerosis	4.88e-05	0.000747	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.87e-05	0.000745	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	4.67e-05	0.000714	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	4.58e-05	0.000701	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	4.47e-05	0.000684	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	4.46e-05	0.000683	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—IGF1—amyotrophic lateral sclerosis	4.35e-05	0.000666	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.34e-05	0.000665	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.19e-05	0.000641	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	4.12e-05	0.000631	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	4.07e-05	0.000623	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	3.97e-05	0.000608	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	3.93e-05	0.000602	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	3.88e-05	0.000595	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	3.75e-05	0.000575	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	3.74e-05	0.000572	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	3.68e-05	0.000563	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	3.47e-05	0.000531	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TPK1—amyotrophic lateral sclerosis	3.4e-05	0.000521	CbGpPWpGaD
Galantamine—ACHE—Metabolism—VAPB—amyotrophic lateral sclerosis	3.4e-05	0.000521	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	3.37e-05	0.000516	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	3.24e-05	0.000496	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.17e-05	0.000486	CbGpPWpGaD
Galantamine—ACHE—Metabolism—VAPA—amyotrophic lateral sclerosis	3.11e-05	0.000477	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	3.1e-05	0.000474	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	3.04e-05	0.000466	CbGpPWpGaD
Galantamine—BCHE—Metabolism—VAPB—amyotrophic lateral sclerosis	3.04e-05	0.000465	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TPK1—amyotrophic lateral sclerosis	3.04e-05	0.000465	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	2.95e-05	0.000452	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.89e-05	0.000443	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.83e-05	0.000433	CbGpPWpGaD
Galantamine—BCHE—Metabolism—VAPA—amyotrophic lateral sclerosis	2.78e-05	0.000425	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	2.75e-05	0.000421	CbGpPWpGaD
Galantamine—ACHE—Metabolism—FIG4—amyotrophic lateral sclerosis	2.72e-05	0.000417	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	2.66e-05	0.000408	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	2.63e-05	0.000403	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.58e-05	0.000395	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	2.55e-05	0.000391	CbGpPWpGaD
Galantamine—ACHE—Metabolism—DAO—amyotrophic lateral sclerosis	2.46e-05	0.000377	CbGpPWpGaD
Galantamine—BCHE—Metabolism—FIG4—amyotrophic lateral sclerosis	2.43e-05	0.000372	CbGpPWpGaD
Galantamine—BCHE—Metabolism—DAO—amyotrophic lateral sclerosis	2.2e-05	0.000336	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	2.18e-05	0.000334	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.12e-05	0.000324	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.96e-05	0.000301	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	1.94e-05	0.000298	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PLB1—amyotrophic lateral sclerosis	1.87e-05	0.000286	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.82e-05	0.000279	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.8e-05	0.000275	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSR—amyotrophic lateral sclerosis	1.72e-05	0.000264	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.67e-05	0.000255	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PLB1—amyotrophic lateral sclerosis	1.66e-05	0.000255	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.57e-05	0.00024	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSR—amyotrophic lateral sclerosis	1.54e-05	0.000235	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CHAT—amyotrophic lateral sclerosis	1.41e-05	0.000216	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.4e-05	0.000214	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	1.4e-05	0.000214	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	1.4e-05	0.000214	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.29e-05	0.000197	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	1.28e-05	0.000196	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CHAT—amyotrophic lateral sclerosis	1.26e-05	0.000193	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.26e-05	0.000193	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.19e-05	0.000182	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.19e-05	0.000182	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.18e-05	0.00018	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.15e-05	0.000176	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	1.12e-05	0.000171	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	1.01e-05	0.000155	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	9.21e-06	0.000141	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	9.13e-06	0.00014	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	9.13e-06	0.00014	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.84e-06	0.000135	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	8.35e-06	0.000128	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	8.22e-06	0.000126	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.88e-06	0.000121	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.76e-06	0.000119	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	7.65e-06	0.000117	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.6e-06	0.000116	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	7.3e-06	0.000112	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	7.06e-06	0.000108	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.98e-06	0.000107	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.78e-06	0.000104	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	6.6e-06	0.000101	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.23e-06	9.53e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	5.8e-06	8.88e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—APOE—amyotrophic lateral sclerosis	5.74e-06	8.79e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—APOE—amyotrophic lateral sclerosis	5.12e-06	7.85e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	5e-06	7.66e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	4.62e-06	7.07e-05	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.94e-06	6.03e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.79e-06	5.8e-05	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.51e-06	5.38e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.12e-06	4.77e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.86e-06	4.38e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	2.36e-06	3.61e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.04e-06	3.12e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.87e-06	2.87e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.61e-06	2.47e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.54e-06	2.36e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.06e-06	1.62e-05	CbGpPWpGaD
